Thermo Fisher Scientific Q2 2026 Earnings Analysis

Thermo Fisher Scientific Q2 2026 Earnings Analysis

More earnings analysis: https://betafinch.com [https://betafinch.com] Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE) [https://betafinch.com/groups/HEALTHCARE)] ────────── **Beta Finch: Thermo Fisher Scientific (TMO) Q2 2026 Earnings Breakdown** ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. Today we're digging into Thermo Fisher Scientific's second quarter 2026 results, and Jordan, this is a genuinely strong print to sink our teeth into. JORDAN: Before we get into it, quick disclaimer for everyone listening. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. ALEX: Right, with that out of the way, let's talk numbers. Thermo Fisher posted revenue of $11.99 billion, up 10% year-over-year. Adjusted operating income jumped 15% to $2.73 billion, and adjusted EPS grew 13% to $6.03 a share. JORDAN: And what jumps out to me is that this wasn't a "beat on cost-cutting" quarter — this was a genuine top-line story. Organic revenue growth came in at 5%, which management explicitly said was about 2 points ahead of their own prior guidance. Margins expanded too — adjusted operating margin hit 22.8%, up 90 basis points. That's the kind of quarter where basically everything worked at once. ALEX: Let's break down where that growth came from. All four end markets grew mid-single-digits or better. Pharma and biotech — their biggest bucket at roughly 60% of revenue — grew mid-single digits, led by bioproduction and clinical research. Industrial and applied also grew mid-single digits, diagnostics and healthcare grew mid-single digits, and even academic and government, which has been the soft spot for a while, returned to growth, albeit low single digits. JORDAN: That academic and government comeback is worth sitting with for a second. CEO Marc Casper was careful not to declare victory there — he said they want to see it "more broad-based" before calling it a real trend. But the U.S. turned slightly positive, Europe was actually quite strong, and interestingly China stayed muted in that segment specifically. So it's a cautious green shoot, not a full recovery. ALEX: Speaking of China — it's about 7.5% of total revenue and grew low single digits, which is its first return to growth in a while. Casper credited that to pharma/biotech and industrial and applied demand, while academic spending there remains flat. He was clear it's not yet accretive to overall company growth, but the trajectory is improving. JORDAN: Now let's talk capital moves, because there's a lot going on here. Thermo Fisher closed the Clario acquisition in late March — that's digital clinical trial endpoint data — and it had a strong first full quarter of ownership. They also closed the filtration and separation business, formerly part of 3M/Solventum, which is showing strong demand and they're actually adding capacity. ALEX: And on the flip side, they're divesting their microbiology business, expected to close in Q3. That business did about $645 million in revenue in 2025. They used the anticipated proceeds to fund a $1 billion share buyback in the quarter — so essentially pre-funding the repurchase ahead of the deal closing. JORDAN: That divestiture does create some near-term drag, worth flagging for anyone modeling this out — management said it reduces 2026 revenue by about $200 million net of retained channel sales, and dings adjusted EPS by about $0.05 this year, growing to roughly $0.15 dilutive in the first full year after close. ALEX: Which makes the guidance raise even more impressive, because it absorbs that headwind and still goes up. New revenue guidance is $47.4 to $48.1 billion, representing 6-8% reported growth. Organic growth guidance moved to "about 4%" for the full year — they kept the 3-4% range but said they now expect to land at the top of it. Adjusted EPS guidance rose to $24.93 to $2 This episode includes AI-generated content.

Intuitive Surgical Q2 2026 Earnings Analysis

More earnings analysis: https://betafinch.com [https://betafinch.com] Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE) [https://betafinch.com/groups/HEALTHCARE)] ────────── ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're diving into Intuitive Surgical's second quarter 2026 results. Before we get going, I do need to say — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. JORDAN: And with that out of the way, Alex, this was actually a pretty strong quarter for Intuitive on paper. ALEX: It was. Revenue up 19% to $2.89 billion, non-GAAP EPS up 28% to $2.80 a share, operating margin at 42%. Total procedures grew 16%, with da Vinci procedures up 15% and Ion — their lung biopsy platform — up a huge 36%. JORDAN: There's a wrinkle in that gross margin number though. It came in at 70%, but $36 million of that was a one-time tariff refund benefit. Strip that out and you're looking at 68.7%, which is still solid, but worth noting when you're comparing quarters. ALEX: Right, and they actually raised full-year gross margin guidance because of that — now 68% to 69%, up from 67.5% to 68.5%. But here's the part that got analysts' attention: U.S. da Vinci procedure growth moderated to 12%, down from 14% in Q1. JORDAN: Yeah, and CFO Jamie Samath was pretty direct about why. They're seeing signs that patients are deferring elective procedures, and they specifically flagged the expiration of ACA enhanced premium subsidies as a factor. Basically, when people's insurance costs go up or coverage gets murkier, they push off surgeries that can wait. ALEX: The CEO, Dave Rosa, made a point of saying the underlying disease burden hasn't changed — people aren't getting healthier, they're just delaying care. Which, if you're an investor, is either reassuring or a "wait and see," depending on how you read it. JORDAN: There's also the GLP-1 story continuing to play out — bariatric procedures in the U.S. declined high-single-digits this quarter as more patients manage weight through drugs like Ozempic instead of surgery. ALEX: Let's talk strategy, because there was a lot packed into this call. The big one: the Extended Use Program. Starting in early 2027, Intuitive plans to increase the number of uses allowed on a subset of their EndoWrist instruments, specifically targeting lower-cost, high-volume benign procedures. JORDAN: This is a classic Intuitive move — they did something similar back in 2020. The idea is: lower the cost per procedure for hospitals, which drives more adoption, which drives more scale. An analyst on the call, Travis Steed, tried to get them to size the financial impact — he was fishing for whether this repeats the roughly 7-point hit to instrument revenue per procedure they saw last time. ALEX: And management wouldn't bite. Jamie Samath said flat out they're not ready to quantify it and will give more detail next quarter. So that's a real overhang to watch heading into 2027 guidance. JORDAN: The other big theme was geographic. China remains genuinely tough — increased domestic robotic competition, pricing pressure, and a new centralized tender process the government is rolling out. Dave Rosa was careful to say it's not quite the same as the volume-based pricing programs we've seen hit other device makers, but it's clearly something to watch. ALEX: Japan, on the other hand, looked more encouraging. New reimbursement policies kicked in June 1st, and they already saw system placements jump — 25 systems in Japan this quarter versus 15 a year ago. JORDAN: And then there's da Vinci 5, which is really the growth engine right now. They placed 468 total da Vinci systems, 246 of those were da Vinci 5, including 114 dual-console setups. The installed base is over 1,700 systems and 15,000 surgeons trained on it already. ALEX: One thing that stood out to me in t This episode includes AI-generated content.

UnitedHealth Q2 2026 Earnings Analysis

More earnings analysis: https://betafinch.com [https://betafinch.com] Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE) [https://betafinch.com/groups/HEALTHCARE)] ────────── **BETA FINCH — UnitedHealth Group (UNH) Q2 2026 Earnings Breakdown** ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into UnitedHealth Group's second quarter 2026 results — a quarter that, honestly, marks a pretty big turnaround story. JORDAN: Big turnaround is right. But before we get into it — quick reminder for everyone listening. ALEX: Right, this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. JORDAN: Good, now let's get into it. ALEX: So let's start with the headline numbers, because they're strong. Adjusted EPS came in at $6.38, up from $4.08 a year ago — that's a huge jump. Revenue was about $112 billion, roughly flat year-over-year, but operating earnings grew 55%. And they raised full-year guidance to a range of $19.50 to $20 a share. JORDAN: What jumps out to me is the medical care ratio — that's basically the percentage of premium revenue that goes out the door in medical claims. It dropped to 86.7% from 89.4% last year. Lower is better for the insurer. Part of that is $860 million in favorable prior-period development, meaning they overestimated costs in prior periods and get to release some of that reserve now. But even stripping that out, the underlying trend is improving. ALEX: And this is really the story CEO Stephen Hemsley told at the top of the call — this is a company about a year into a restructuring after a rough stretch, and he was pretty clear: "we will remain restless." He's not declaring victory, but the discipline is showing up in the numbers. JORDAN: Let's talk segments, because the picture is genuinely split. Medicare Advantage was the star of the quarter. Membership retention beat expectations, they now expect MA enrollment to decline by only about 1.1 million instead of more, and Medicare margins are tracking above 3% for the year. Medical trend also came in below their original 10% estimate — helped by benefit redesign, network curation, and honestly, a milder flu season. ALEX: Meanwhile, commercial is the soft spot. Cost trends are running modestly above 11%, worse than they'd hoped. Management pointed to two specific culprits: the No Surprises Act's arbitration process — which they say is being exploited, with average payouts to out-of-network providers now 11 times what Medicare would pay — and more aggressive provider billing and coding practices. JORDAN: That arbitration point was one of the more eye-opening moments in the Q&A. Executive Dan Kueter said roughly 60% of all arbitration cases are now brought by just five entities, and 40% of claims entering the process are actually ineligible to begin with. It's clogging the system and driving costs up. The upshot: commercial margin recovery, which they'd hoped to complete by 2027, is now going to take longer. Not derailed, in their words — just delayed. ALEX: Medicaid, meanwhile, is basically playing out as planned — margins pressured, expected to land between -1% and -1.7% for the year, as state reimbursement rates lag behind medical cost growth. Nothing new there, just a slow grind toward better alignment with states. JORDAN: Now let's flip to Optum, the services side of the business, because that's where a lot of the AI story lives. Optum Health — their value-based care arm — is showing real improvement: a roughly 10% reduction in hospitalizations in regions where they've rolled out new care transition programs, and patient satisfaction up about 5% year-over-year. ALEX: Optum Rx, the pharmacy benefit manager, is leaning hard into transparency — they're on track to have more than 95% of clients on 100% rebate pass-through by year-end. This episode includes AI-generated content.

Abbott Laboratories Q2 2026 Earnings Analysis

More earnings analysis: https://betafinch.com [https://betafinch.com] Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE) [https://betafinch.com/groups/HEALTHCARE)], INCOME (https://betafinch.com/groups/INCOME) [https://betafinch.com/groups/INCOME)] ────────── Welcome to Beta Finch, your AI-powered earnings breakdown. Here's the Abbott Labs (ABT) Q2 2026 script. --- **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into Abbott Laboratories' second quarter 2026 results. Before we jump in, quick disclaimer — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. **JORDAN:** Thanks, Alex. And there's a lot to like in this print. Let's start with the headline numbers. **ALEX:** Right, so Abbott posted sales growth of 4.8% for the quarter — that's an acceleration from the last two quarters — and adjusted EPS of $1.31, which beat both the midpoint of their guidance and consensus estimates. **JORDAN:** And here's the part investors really zeroed in on — Abbott didn't just reaffirm full-year sales guidance of 6.5% to 7.5%, they actually raised their EPS guidance range to $5.45 to $5.60. CEO Robert Ford was pretty clear that gross margin expansion is doing a lot of the heavy lifting there — margins came in at 58%, up 100 basis points year-over-year. **ALEX:** Let's talk segments, because there's a real story of divergence here. Medical devices grew 8.5%, led by electrophysiology — that's the heart rhythm and ablation business — which grew in the low teens. EPD, their emerging markets pharma division, grew 9%, powered by India, Latin America, and Southeast Asia. **JORDAN:** Diagnostics was mixed. Core lab was strong, U.S. up 7.5%. But rapid and molecular diagnostics — that's respiratory testing — declined 8% because it was just a weak flu and respiratory virus season. That's expected and temporary though, not a demand problem. **ALEX:** And then nutrition — this is the comeback story of the quarter. Sales came in ahead of expectations for the second straight quarter, up sequentially by $125 million. Ensure retail consumption in the U.S. is up double digits. **JORDAN:** Yeah, that's the price increases from late last year finally working through the system — volumes are responding well now that consumers have adjusted. Management is now framing nutrition as a sustainable 2-4% grower going forward. **ALEX:** Let's get into the strategic stuff, because there's a lot of pipeline news. Abbott completed enrollment in its coronary IVL trial, filed with the FDA for the Amulet 360 left atrial appendage device, and got a CE mark in Europe for Libre Duo — which is notable, it's the world's first dual glucose-ketone monitoring sensor, designed to help prevent diabetic ketoacidosis. **JORDAN:** The CGM story is worth sitting with for a second. Diabetes care crossed $2 billion in quarterly sales, growing 9.5%. Now, one analyst on the call kind of poked at that number as "only" 9.5%, and Ford pushed back — reasonably, I'd say. He pointed out there's 75 to 80 million people globally who could realistically use a CGM, and only 15 million currently do. Growth right now is basically waiting on reimbursement expansion, especially the big one: U.S. Type 2 non-insulin Medicare coverage, which could unlock roughly 10 million beneficiaries. Ford said that could happen this fall but wouldn't pin down an exact date. **ALEX:** They're also planning a fifth manufacturing facility for CGM sensors — a billion-dollar investment — because they expect to hit capacity limits at their current facility within a couple years. That's a pretty strong signal of how bullish they are on long-term demand. **JORDAN:** One theme that came up repeatedly in the Q&A was this investor worry about decelerating hospital procedure volumes — tied to ACA enrollment changes and Medicaid dynamics. This episode includes AI-generated content.

Medtronic Q4 2026 Earnings Analysis

More earnings analysis: https://betafinch.com [https://betafinch.com] Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE) [https://betafinch.com/groups/HEALTHCARE)] ────────── # Beta Finch Podcast Script: Medtronic Q4 2026 Earnings **ALEX:** Welcome back to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that matter. I'm Alex, and I'm joined as always by my co-host Jordan. Today we're unpacking Medtronic's fourth quarter 2026 results, and folks, this is a company that's clearly hitting its stride. Before we dive in, I need to share an important disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. **JORDAN:** Thanks Alex, and wow - where do we even start with Medtronic? These numbers are impressive. The company just posted $9.8 billion in Q4 revenue, up nearly 10% reported and 6.6% organically. But here's what really caught my attention - this caps off their strongest annual performance in a decade. **ALEX:** That's right, Jordan. For the full fiscal year, they hit $36.4 billion in revenue with 8.4% reported growth and 5.8% organic growth. CEO Geoff Martha was clearly proud of these results, calling it a reflection of their "commitment to operational rigor" while investing in durable growth. But let's talk about what's really driving this performance. **JORDAN:** The star of the show has got to be their Cardiac Ablation Solutions business - or CAS. This division delivered 78% worldwide growth and gained 8 points of U.S. market share. Their PFA technology saw 145% global growth, with their Sphere-9 catheter continuing to show "broad versatility," as Martha put it. **ALEX:** And here's what's really exciting about CAS - they're still in the "early innings," as CFO Thierry Pieton noted. The company increased their installed base by 40% just in the fourth quarter alone. They're now annualizing over $2 billion in revenue and are on track to hit that $2 billion trailing mark in the first quarter of fiscal 2027. That's massive scale in a high-growth market. **JORDAN:** What I found fascinating was Martha's comment about "completely surrounding the electrophysiology space." They're not just selling one product - they're building an entire ecosystem. They launched Sphere-9 in Japan, got FDA approval for a U.S. VT pivotal trial, and even announced two targeted investments in ICE catheter technology this morning. **ALEX:** Speaking of investments, let's talk about their capital allocation strategy because this is where you really see the company's long-term vision. In Q4 alone, they closed or announced nearly $2 billion in additional investments through M&A and venture deals. They acquired CathWorks for their AI-powered FFRangio system, announced plans to buy Scientia for neurovascular guidewire tech, and made investments in everything from chronic pain management to pulmonary artery denervation. **JORDAN:** That's a great point, Alex. And it's not just about buying technology - it's about strategic positioning. Take their Symplicity Spyral system for treating hypertension. This business is now annualizing at $100 million, and they've doubled their weekly procedure volumes since getting the NCD coverage decision. Martha emphasized that 18 million Americans still have uncontrolled hypertension despite multiple medications - that's a massive addressable market. **ALEX:** Let's shift to the numbers that investors will be watching closely. For fiscal 2027, Medtronic is guiding to organic revenue growth of 6.75% to 7.25%. Now, there's an extra selling week baked into that, which adds about 125 basis points, but even adjusting for that, we're looking at solid mid-single-digit growth acceleration. **JORDAN:** The guidance is particularly interesting because of how they're handling the MiniMed diabetes business. They completed the IPO in March, but This episode includes AI-generated content.